 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H27N3O3S |
| Molar mass | 401.53 g·mol−1 |
| 3D model (JSmol) | |
| |
Sonepiprazole (U-101,387,PNU-101,387-G) is adrug of thephenylpiperazine class which acts as a highlyselectiveD4 receptorantagonist.[1] In animals, unlikeD2 receptor antagonists likehaloperidol, sonepiprazole does not block the behavioral effects ofamphetamine orapomorphine, does not alter spontaneouslocomotor activity on its own, and lacksextrapyramidal andneuroendocrine effects.[2] However, it does reverse theprepulse inhibition deficits induced by apomorphine,[3] and has also been shown to enhancecortical activity and inhibitstress-inducedcognitive impairment.[4][5] As a result, it was investigated as anantipsychotic for the treatment ofschizophrenia in aplacebo-controlledclinical trial, but in contrast to its comparatorolanzapine no benefits were found and it was not researched further for this indication.[6][7]
